nitroglycerin has been researched along with everolimus in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brugaletta, S; Bruining, N; de Bruyne, B; Dorange, C; Dudek, D; Farooq, V; Garcia-Garcia, HM; Heo, JH; Koolen, J; McClean, D; Onuma, Y; Ormiston, JA; Rapoza, R; Serruys, PW; Smits, PC; van Geuns, RJ; Veldhof, S | 1 |
| Chyrchel, M; Dudek, D; Dziewierz, A | 1 |
| Depukat, R; Dudek, D; Ediebah, D; Kaluza, GL; Malinowski, KP; Onuma, Y; Rzeszutko, Ł; Serruys, PW; Sotomi, Y; Staehr, P; Veldhof, S; Zasada, W | 1 |
| Adeliño, R; Altisent, OA; Amat-Santos, IJ; Fernández-Vázquez, F; Gómez, I; Goncalves-Ramírez, LR; Gutiérrez, H; Pérez de Prado, A; Puri, R; San Román, A | 1 |
1 review(s) available for nitroglycerin and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for nitroglycerin and everolimus
| Article | Year |
|---|---|
Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therap
Topics: Absorbable Implants; Acetylcholine; Aged; Coronary Vessels; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; Nitroglycerin; Plaque, Atherosclerotic; Sirolimus; Tissue Scaffolds; Vasodilation; Vasodilator Agents; Vasomotor System | 2012 |
Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation.
Topics: Absorbable Implants; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Everolimus; Humans; Nitroglycerin; Percutaneous Coronary Intervention; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vasoconstriction; Vasodilation; Vasodilator Agents; Vasomotor System | 2017 |
2 other study(ies) available for nitroglycerin and everolimus
| Article | Year |
|---|---|
Recurrent coronary vasospasm-induced acute coronary syndrome complicated by cardiac arrest.
Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Cardiopulmonary Resuscitation; Cardiovascular Agents; Coronary Angiography; Coronary Vasospasm; Coronary Vessels; Drug-Eluting Stents; Electrocardiography; Everolimus; Heart Arrest; Humans; Male; Middle Aged; Nitroglycerin; Percutaneous Coronary Intervention; Recurrence; Treatment Outcome | 2015 |
Structural and Functional Evaluation of Coronary Arteries Treated With ABSORB Bioresorbable Vascular Scaffold at 5-Year Follow-Up.
Topics: Absorbable Implants; Acetylcholine; Coronary Angiography; Coronary Vessels; Drug-Eluting Stents; Everolimus; Follow-Up Studies; Humans; Nitroglycerin; Percutaneous Coronary Intervention; Prosthesis Design; Tomography, Optical Coherence; Treatment Outcome | 2022 |